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Abstract
Background: Canine generalised demodicosis is an inflammatory parasitic skin disease caused by an excessive
proliferation of Demodex spp. Generalized demodicosis is a severe skin disease, that can be life threatening if not
treated properly. Many of the current treatment options are not licensed for the treatment of generalised demodicosis,
it have a low safety margin and may be poorly efficacious and time-consuming for the owner; there is a need for
a safe, efficacious treatment for canine demodicosis. Our objective was to systematically review the literature to
determine the most effective and safe topical or systemic therapy for canine generalised demodicosis. Single case
reports and case series with fewer than five patients were not reviewed as they were considered to be poor
quality evidence. A detailed literature search identified 21 relevant clinical trials and these were critically assessed.
Results: The analysis of the best available evidence on March 5, 2018, suggests that six are the most effective
and safe treatments for generalised canine demodicosis including (in alphabetical order): doramectin (oral or
parenteral); fluralaner (oral); imidacloprid/moxidectin (topical); ivermectin (oral, not as first choice treatment);
milbemycin oxime (oral); and sarolaner (oral). There was insufficient evidence to allow comment on the
appropriateness of other treatment protocols for canine generalised demodicosis in this CAT.
Conclusions: In our critical appraisal of the best scientific literature, there is evidence for recommending the use
of 6 therapeutic options against demodectic mange. Further, in vivo, controlled, randomized and blinded clinical
trials are required, to evaluate new therapies.
Keywords: Canine generalised demodicosis, Demodectic mange, Treatment, Efficacy, Therapeutic protocol,
Topical therapy, Systemic therapy
Background
Canine generalized demodicosis in an inflammatory
parasitic skin disease, caused by an excessive prolifera-
tion of Demodex spp mites, which are normal skin
commensals in most dogs. According to the extent of
the lesions, demodicosis is classified as either localized
or generalized. The generalized form can be one of the
most severe canine skin disease, and can be life threat-
ening if not treated adequately and promptly [1].
Current available therapeutic options for the treatment
of generalised canine demodicosis include many drugs
of variable efficacy. Some of these drugs are registered
for this use whereas others are not, and some have po-
tentially severe adverse effects [2, 3]. The aim of this
critically appraised topic is evaluate the best scientific
evidence, to identify the most effective and safe topical
or systemic therapy for canine generalised demodicosis.
Clinical scenario
The patient is a one-year old, intact female, stray Border
collie cross. She is malnourished (BCS 3/5), and exhibits
intense pruritus and mild enlargement of palpable lymph
nodes. On dermatologic examination, there are wide-
spread alopecic patches, crusts with serous-haemorrhagic/
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purulent exudate, mostly confluent on the head and face,
legs, hips and abdomen. Her coat has poor quality and
shows scaling, whilst the skin on the abdomen and fore-
legs is erythematous, with numerous comedones. The case
history corresponds to a generalised exfoliative dermatitis
associated with a multifocal, itchy, erosive and crusty
dermatitis.
Skin cytology, hair plucking, and five deep skin scrap-
ings are performed and the material is examined under
the microscope: neutrophil granulocytes with phagocy-
tosed cocci and many Demodex spp (adults, larval
forms and eggs) are visible. The diagnosis is juvenile-
onset generalised demodectic mange associated with
secondary bacterial infection; the question is which
therapeutic protocol will result in healing of this young
stray dog with minimal risk.
Structured question
In a dog affected with generalised demodicosis, which
is the most effective, rapid and safe topical or systemic
therapy to ensure complete clinical and parasitological
remission?
Methods
The PUBMED, Web of Science (Science Citation Index
Expanded) and CAB Abstract databases were searched
on March 5, 2018 using the following string: (dog OR
dogs OR canine) and (demodectic mange OR demodi-
cosis) and (therapy OR treatment OR therapeutics OR
therapeutic protocol OR efficacy), with no limitations
of date and language. We excluded congress proceed-
ings and book chapters.
Results
Our literature search identified 124, 185 and 485 cita-
tions in PUBMED, Web of Science and CAB Abstract
databases, respectively. Citations were initially assessed
to identify articles reporting original information; re-
view papers were not considered further. Abstracts
were then read and pertinent articles were read in full.
The bibliography of these articles was examined further
for additional pertinent citations. We only selected on-
line available clinical trials testing an effective and safe
topical or systemic therapy against generalized demodi-
cosis, with or without control groups, that provided a
population of at least 5 naturally affected dogs and
where the diagnosis was made performing multiple
(three/five) deep skin scrapings of which at least one
positive. In the included studies, the number and viabil-
ity of the Demodex spp. microscopically observed at the
time of diagnosis and the presence/absence at each
subsequent follow up had to be reported to evaluate
the efficacy of the therapeutic protocol, that is multiple
negative skin scrapings.
After the analysis of all the bibliography, we found 34
pertinent citations. There were 13 duplicated articles
and therefore only 21 fulfilled our criteria and were in-
cluded for further analysis. [4–24] All 21 studies are
primary studies, reported between 1983 and 2018, all
written in English except one Brazilian study written in
Portuguese (Table 1).
The 21 selected articles assess the efficacy of 12
different drugs against canine generalised demodicosis:
4 for topical use (Amitraz [10]; Imidacloprid + Moxi-
dectin [8, 11, 16, 18–20]; Amitraz + Metaflumizone
[10, 14]; Amitraz + Fipronil + methoprene [14]) and
8 systemic treatment (Milbemicine Oxime [5, 7, 8];
Doramectin [12, 15, 22]; Moxidectin [9, 13]; Ivermectin
[6, 9, 16, 17]; Fluralaner [18, 24]; Afoxolaner [20];
Sarolaner [19, 23]; Lotilaner [21]).
These studies comply with our inclusion criteria and
the focussed clinical question, but have very different
study designs. We therefore analysed the scientific
quality of each study using following parameters to
determine the risk of biased evaluation of treatment
efficacy, as summarised in Table 2.
– Levels of evidence: randomized clinical trials (RCTs)
with low risk of bias level IA, medium risk of bias IB
and high risk of bias IC. Controlled trials without
randomization or blinding with low risk of bias level
IIA, medium risk of bias IIB, high risk IIC. Open
uncontrolled trials level IV.
– Randomization: presence of a method of generation
of the randomization sequence and concealment of
the allocation of participants to the intervention
groups by the people recruiting the participants.
Score: 0 (no) – 1 (yes).
– Blinding: trial participants were kept unaware of the
treatment allocation. Score: 0 (no) – 1 (yes).
– Similarity between groups: populations allocated
to different groups in the trial share the same
characteristics from the beginning and during
the study. Score: 0 (no), 1 (deduced form the
text), 2 (yes).
– Equal treatment of groups: populations allocated to
different groups in the trial have been treated
similarly except for the therapy. Score: 0 (no),
1 (deduced form the text), 2 (yes).
– Presence of at least 12 months follow up: score:
0 (no) – 1 (yes).
– Group size: score: 1 (10–20 dogs), 2 (> 20–40 dogs),
3 (> 40 dogs).
As described in Table 2, at the end of this phase of
quality assessment, every study achieved a total score
and was thus graded as: conclusive [8, 16], highly
suggestive [4, 7, 9, 17, 22, 23], suggestive [5, 6, 11–14,
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18–21, 24] or inconclusive [10, 15]. Inconclusive refer-
ences were immediately excluded.
To emphasise the overall strength of selected stud-
ies, we evaluated conclusive, preponderant and sug-
gestive studies for each therapy protocol used,
systemic (Table 3) or topical (Table 4), considering
the following variables:
– adverse effects: None: score 3; Yes, mild and rare
(< 10%): score 2; Yes, moderate and common (>
10%): score 1; Yes, severe and common: score 0.
The adverse effects only for the references with
score 2, 1 and 0 are detailed in Table 5.
– treatment duration: More than 4 months: score 1;
From 2 to 4 months: score 2; less than 2 months:
score 3.
– efficacy: Percentage of cured dogs, or percentage
of microscopic reduction of mites count. Efficacy
< 60%: score 1; > 60 < 80%: score 2; > 80 < 100%:
score 3.
Table 1 Details of included articles
Reference Year Authors Title
[4] 1983 S.D. Folz et al Chemotherapeutic treatment of naturally acquired
generalized demodicosis.
[5] 1995 W.H. Miller et al Clinical efficacy of increased dosages of milbemycin
oxime for treatment of generalized demodicosis in adult dogs.
[6] 1995 Z. Ristic et al Ivermectin for treatment of generalized demodicosis in dogs.
[7] 2003 B.R. Holm Efficacy of milbemycin oxime in the treatment of canine
generalized demodicosis: a retrospective study of 99 dogs (1995–2000)
[8] 2005 J. Heine et al Evaluation of the efficacy and safety of imidacloprid 10% plus moxidectin
2.5% spot-on in the treatment of generalized demodicosis in dogs:
results of a European field study.
[9] 2006 E.H. Delayte et al Eficàcia das lactonas macrocìclicas sistemicas (ivermectina e
moxidectina) na terapia da demodicidose canina generalizada.
[10] 2007 L.J. Fourie et al Efficacy of a novel formulation of metaflumizone plus amitraz for the
treatment of demodectic mange in dogs.
[11] 2009 L.J. Fourie et al Comparative efficacy and safety of two treatment regimens with a
topically applied combination of imidacloprid and moxidectin
(Advocate) against generalised demodicosis in dogs.
[12] 2010 Murayama et al Efficacy of weekly oral doramectin treatment in canine demodicosis.
[13] 2000 R. Wagner et al Field efficacy of moxidectin in dogs and rabbits naturally infested with
Sarcoptes spp., Demodex spp. and Psoroptes spp. mites.
[14] 2013 L.J. Fourie et al Efficacy of a topical application of Certifect (fipronil 6.26% w/v, amitraz
7.48% w/v, (S)-methoprene 5,63% w/v) for the treatment of
canine generalized demodicosis.
[15] 2015 J.H.C. Hutt Treatment of canine generalized demodicosis using weekly injections
of doramectin: 232 cases in the USA (2002–2012).
[16] 2009 T.E. Paterson et al Treatment of canine-generalized demodicosis: a blind, randomized
clinical trial comparing the efficacy of Advocate (Bayer
Animal Health) with ivermectin.
[17] 2014 T.E. Paterson et al Canine generalized demodicosis treated with varying doses of a 2.5%
moxidectin + 10% imidacloprid spot-on and oral ivermectin: parasiticidal
effects and long-term treatment outcomes.
[18] 2015 L.J. Fourie et al Efficacy of orally administered fluralaner (Bravecto) or topically applied
imidacloprid/moxidectin (Advocate) against generalized demodicosis in dogs.
19 2016 R.H. Six et al Efficacy of sarolaner, a novel oral isoxazoline, against two common mite
infestations in dogs: Demodex spp. and Otodectes cynotis.
[20] 2016 F. Beugnet et al Efficacy of oral afoxolaner for the treatment of canine generalised demodicosis
[21] 2017 D.E Snyder et al Efficacy of lotilaner (Credelio™), a novel oral isoxazoline against naturally
occurring mange mite infestations in dogs caused by Demodex spp.
[22] 2018 A.M.Cordero et al Doramectin in the treatment of generalized demodicosis.
[23] 2018 C. Becskei et al Efficacy and safety of sarolaner against generalized
demodicosis in dogs in European countries: a non-inferiority study.
[24] 2018 L.Duangkaew et al A field trial in Thailand of the efficacy of oral fluralaner for the
treatment of dogs with generalized demodicosis.
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Discussion
There is insufficient evidence for commenting on the
use of some evaluated treatment protocols of this CAT.
The topical use of amitraz liquid concentrate licensed
for the treatment of demodicosis cannot be recom-
mended as there was only a single study reporting this
treatment and this had a follow up of less than 12
months [4]. Also both amitraz-based spot-on treat-
ments were evaluated in a single study [14] without
follow-up of at least 12 months. With regard to the sys-
temic therapies, the oral administration of moxidectin,
evaluated in two unrandomized and unblinded studies
[15, 19], cannot be recommended, due to the high
percentage (37%) and severity of side effects, whilst the
administration of afoxolaner [20] and lotilaner [21],
despite appearing very effective easy to administer and
safe in the treatment of demodectic mange, cannot be
recommended, because there is only one reference
reporting use of each molecule and follow up was less
than 12 months.
There is evidence for recommending the use of 6
drugs: the first is 10% imidacloprid + 2.5% moxidectin
spot-on (licensed for treatment of demodectic mange),
that was the most represented topical compound in
this CAT; 8 randomized, blinded and controlled (ex-
cept [11]) clinical trials assessed its efficacy [8, 11, 16–
20, 23] with an adequate follow up (except [18–20]); at
different application intervals. The efficacy of 10% imi-
dacloprid + 2.5% moxidectin spot-on was demon-
strated with monthly application, especially in dogs
affected with juvenile generalised demodicosis or with
mild forms; its efficacy increased notably with the fre-
quency of application, without reported side effects.
The European approved label instructions for the use
of 10% imidacloprid + 2.5% moxidectin recommend
monthly use with the possibility of increasing the dur-
ation and/or the frequency of application especially in
severe cases: biweekly and weekly applications do not
represent an off-label use of this drug.
Oral administration of milbemycin oxime (licensed
for the treatment of demodicosis), was evaluated in 3
clinical trials [5, 7, 8]. This drug was very effective, es-
pecially at the highest dosage in severe cases, with
moderateor no reported adverse reactions.
The use of doramectin (not licensed for the treat-
ment of demodicosis) was studied in two reports with
adequate follow up [12, 22], but only one randomized
and blinded trial [22]: subcutaneous injection or oral
Table 2 Evaluation of evidence. The studies are categorized as conclusive (total score 8–9), highly suggestive (total score 6–7),
suggestive (total score 4–5) and inconclusive (total score ≤ 3)
Reference Level of
evidence
Randomization Blinding Group
size
Similarity
between groups
Equal treatment
of groups
Follow
up
SCORE Categorization
[4] IIB 1 0 3 1 1 0 6 HIGHLY SUGGESTIVE
[5] IIC 0 0 2 1 1 1 5 SUGGESTIVE
[6] IIC 0 0 1 1 1 1 4 SUGGESTIVE
[7] IV 0 0 3 1 1 1 6 HIGHLY SUGGESTIVE
[8] IB 1 1 3 2 1 0 8 CONCLUSIVE
[9] IIC 0 0 3 1 1 1 6 HIGHLY SUGGESTIVE
[10] IIC 0 0 1 1 1 0 3 INCONCLUSIVE
[11] IIB 1 0 1 1 1 1 5 SUGGESTIVE
[12] IV 0 0 2 1 1 1 5 SUGGESTIVE
[13] IIC 0 0 1 1 1 1 4 SUGGESTIVE
[14] IB 1 1 1 1 1 0 5 SUGGESTIVE
[15] IV 0 0 3 0 0 0 3 INCONCLUSIVE
[16] IB 1 1 3 2 1 1 9 CONCLUSIVE
[17] IB 1 1 2 1 1 1 7 HIGHLY SUGGESTIVE
[18] IB 1 1 1 1 1 0 5 SUGGESTIVE
[19] IB 1 1 1 1 1 0 5 SUGGESTIVE
[20] IB 1 1 1 1 1 0 5 SUGGESTIVE
[21] IIC 0 0 1 2 1 0 4 SUGGESTIVE
[22] IC 1 0 1 2 1 1 6 HIGHLY SUGGESTIVE
[23] IC 1 1 3 1 1 0 7 HIGHLY SUGGESTIVE
[24] IV 0 0 3 1 1 0 5 SUGGESTIVE
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Table 3 Efficacy of systemic therapies against generalised demodicosis in dogs. References 9 and 22 are repeated twice because
two different protocols were tested in the same study
Reference Therapy Posology Adverse
effects
Treatment
duration
Efficacy
[5] MILBEMYCIN OXIME 1–2 mg/kg per os every 24 h. not reported 2 3
[6] IVERMECTIN 0.6 mg/kg per os every 24 h. 2 2 3
[7] MILBEMYCINE OXIME 0.5–1.6 mg/kg per os every 24 h. 3 2 3
[8] MILBEMYCIN OXIME 0.5–1 mg/kg or 1–2 mg/kg every
24 h. for 4 weeks.
1 2 3
[9] IVERMECTIN tablets 0.6 mg/kg per os every 24 h. 1 1 3
[9] MOXIDECTIN 0.5 mg/kg per os every 72 h. 1 1 3
[12] DORAMECTIN 0.6 mg/kg per os weekly. 2 2 2
[13] MOXIDECTIN 0.4 mg/kg per os every 24 h. 1 2 3
[16] IVERMECTIN 0.5 mg/kg per os every 24 h. 3 2 3
[17] IVERMECTIN 0.5 mg/kg per os every 24 h. 1 1 3
[18] FLURALANER 25 mg/kg per os once. 3 2 3
[19] SAROLANER 2mg/kg per os every 30 days
for 3 times.
3 2 3
[20] AFOXOLANER 2.5 mg/kg per os every 2 weeks
for 4 times.
3 2 3
[21] LOTILANER 20 mg/kg per os monthly
for 3 times.
3 2 3
[22] DORAMECTIN 600 μg/kg s.c. once a week 3 2 3
[22] DORAMECTIN 600 μg/kg per os twice a week 3 2 3
[23] SAROLANER 2–4 mg/kg per os every 30 days 3 2 3
[24] FLURALANER 25–50 mg/kg per os once or
every 12 weeks
3 2 3
Table 4 Efficacy of topical therapies against generalised demodicosis in dogs. Reference 14 is repeated twice because two different
protocols were tested in the same study
Reference Therapy Posology Adverse
effects
Treatment
duration
Efficacy
[4] AMITRAZ From 3 to 6 applications at 14-days
intervals.
3 2 3
[8] IMIDACLOPRID+MOXIDECTIN From 2 to 4 applications at 28-days
intervals.
3 2 3
[11] IMIDACLOPRID+MOXIDECTIN Group 1 treated at 28-days intervals
max 4 times; group 2 at 7-days
intervals max 16 times.
2 1 3 (Group 1)
3 (Group 2)
[14] FIPRONIL + METHOPRENE +
AMITRAZ
Group 1 treated at 28-days intervals;
group 2 treated at 14-days intervals.
3 2 3 (Group 1)
3 (Group 2)
[14] METAFLUMIZONE + AMITRAZ Group 3 treated at 28-days intervals. 3 2 3
[16] IMIDACLOPRID+MOXIDECTIN ADV1 treated monthly; ADV2
biweekly; ADV4 weekly.
3 2 1 (ADV1) 2 (ADV2)
AND 3 (ADV4)
[17] IMIDACLOPRID+MOXIDECTIN ADV1 treated monthly; ADV2
biweekly; ADV4 weekly.
3 1 1 (ADV1) 2 (ADV2)
AND 3 (ADV3)
[18] IMIDACLOPRID+MOXIDECTIN 3 applications at 28-days intervals. 3 2 3
[19] IMIDACLOPRID+MOXIDECTIN Weekly from day 0 to day 81. 3 2 3
[20] IMIDACLOPRID+MOXIDECTIN 4 applications at 14-days intervals. 3 2 3
[23] IMIDACLOPRID+MOXIDECTIN From 2 to 6 applications at 7 or
28-days intervals
3 2 3
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administration of this macrocyclic lactone are equally
effective against demodectic mange in dogs, especially
at the dosage of 0.6 mg/kg twice a week. Only 1 subject
in one of the two studies [12] showed side effects
(transient ataxia).
Only two molecules belonging to the class of isoxazoline,
fluralaner and sarolaner (recently registered for the pur-
pose), were adequately studied for the treatment of demo-
dectic mange [18, 19, 23, 24]. Although in three studies
[18, 19, 23], adequate follow-up was not performed, there
is enough evidence for recommending the use of these
novel isoxazolines against canine demodicosis, because of
their ease of use, safety (no adverse effects) and efficacy.
Finally, ivermectin has been widely used for the treat-
ment of generalised demodicosis in dogs, although it is
not licensed for this purpose and a formulation for dogs
is not available. Four clinical trials [6, 9, 16, 17], tested
the efficacy of oral administration of injectable ivermectin
for cattle [6, 16, 17] and of a pharmaceutical speciality
formulated for the purpose [9]; to achieve clinical and
parasitological cure treatment duration was more than 3
months, but the efficacy was excellent. However mild and
moderate adverse reactions occurred in these reviewed
trials (three out of four) and specials attention must be
paid in collies dogs. Despite oral ivermectin is extremely
effective against Demodex spp. and there is good evi-
dence for its use, because of the common side effects is
not recommended as first choice treatment.
Conclusion
This critically appraised topic, based on evaluation of
the current evidence, demonstrates that only 6 treat-
ment regimens can be recommended for use against
canine generalised demodicosis (moxidectin + imida-
cloprid spot-on; oral milbemycin oxime, oral or paren-
teral doramectin, oral fluralaner oral sarolaner and,
Table 5 Detail of adverse effects of systemic and topical therapies with score 2, 1 and 0. Reference 9 is repeated twice because two
different protocols were tested in the same study
Reference Therapy Adverse effects score Type of adverse event N. of cases
[6] IVERMECTIN 2 Mild toxicosis 1
[8] MILBEMICINE OXIME 1 Diarrhoea and neurological signs 7
[9] IVERMECTIN tablets 1 • Ataxia 3
• Lethargia 3
• Sialorrhea 2
• Disorexia 1
• Apathy 1
• Aggressive behavior 1
[9] MOXIDECTIN 1 • Emesis 8
• Disorexia 2
• Anorexia 2
• Sialorrhea 2
• Adipsia 1
• Diarrhea 1
• Lethargia 4
• Apatia 2
• Myoclonia 1
• Enanthema 1
[11] IMIDACLOPRID+MOXIDECTIN 2 • Transient erythema 1
• Scaling 1
[12] DORAMECTIN 2 Mild ataxia 1
[13] MOXIDECTIN 1 • Ataxia 2
• Lethargia, vomiting 1
[17] IVERMECTIN 1 • Transient neurotoxicosis with bilateral
mydriasis, decreased to absent pupillary
light response, ataxia and generalized muscle
weakness, vomiting, coma (1 dog)
4
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not as first choice treatment, oral ivermectin). The
remaining therapies, although sometimes effective, have
not been adequately evaluated. For future studies, we
recommend in vivo, randomized, blinded and controlled
clinical trials, providing a post treatment follow up of
12 months, so that relapses are immediately detected.
The efficacy of any new compounds should be tested
properly, to help veterinarians in the cure of this wide-
spread dermatological disease.
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